Daily Endocrinology Research Analysis
Analyzed 111 papers and selected 3 impactful papers.
Summary
Two mechanistic diabetes studies reveal complementary immune–beta cell strategies: a GLP1–estradiol conjugate synergized with low-dose anti-CD3 to halve autoimmune diabetes incidence in NOD mice, while a selective FFAR2 agonist activated intestinal ILC3 and Treg cells to ameliorate hyperglycemia via IL-22–dependent pathways. A 10-year, 5,040-patient Korean registry provides reassuring long-term safety data for pediatric recombinant human growth hormone therapy, with malignancy rates comparable to national expectations.
Research Themes
- Combination immunotherapy and β-cell protection in type 1 diabetes
- Gut–immune–pancreas axis targeting via FFAR2 and ILC3 activation
- Long-term pharmacoepidemiologic safety of pediatric recombinant growth hormone
Selected Articles
1. GLP1-E2 therapy delays autoimmune diabetes in late-stage prediabetic NOD mice and potentiates low-dose anti-CD3 therapy for enhanced disease protection.
In late-prediabetic NOD mice, a GLP1–17β-estradiol conjugate combined with a short, low-dose anti-CD3 course halved diabetes incidence (38% vs 77%) and delayed onset by 6 weeks, outperforming either monotherapy. Spatial transcriptomics indicated complementary mechanisms: anti-CD3 largely restored β-cell identity while GLP1–E2 reduced β-cell stress and immunogenicity, together preserving β-cell mass.
Impact: This preclinical study introduces a rational combination therapy that co-targets immune dysregulation and β-cell fragility, achieving durable protection in a stringent T1D model with spatially resolved mechanistic insights.
Clinical Implications: Findings support testing GLP1-based β-cell–protective agents to potentiate anti-CD3 in stage 2–3 T1D, aiming to extend remission and preserve β-cell function. Biomarker-guided trials leveraging spatial signatures may optimize patient selection.
Key Findings
- Combination GLP1–E2 + low-dose anti-CD3 reduced diabetes incidence to 38% vs 77% in controls and 61–66% with monotherapy.
- Disease onset was delayed by 6 weeks with combination therapy, with protection persisting 5 weeks post-treatment.
- Spatial transcriptomics showed attenuation of β-cell stress, dedifferentiation (e.g., CD81), antigen presentation, and inflammatory gene programs; anti-CD3 restored identity while GLP1–E2 reduced stress/immunogenicity.
- Islet immune infiltration decreased with GLP1–E2 to a similar extent as anti-CD3.
- β-cell mass was better preserved in treated mice compared with new-onset diabetic mice.
Methodological Strengths
- Randomized multi-arm preclinical design with complementary monotherapy and combination arms.
- Deep mechanistic profiling using spatial transcriptomics and histology (CD81, TUNEL) linking cellular programs to outcomes.
Limitations
- Preclinical female NOD mouse study; human translatability and sex differences remain to be established.
- Follow-up duration was limited (protection assessed up to 5 weeks post-treatment); long-term durability unknown.
Future Directions: Early-phase clinical trials combining β-cell–protective incretin conjugates with anti-CD3 in presymptomatic or new-onset T1D, with spatial/omic biomarkers to monitor β-cell stress and identity.
AIMS/HYPOTHESIS: Anti-CD3 monoclonal antibody (aCD3) delays progression to stage 3 type 1 diabetes in high-risk individuals by modulating autoimmune activity. Nevertheless, responses remain variable and transient, with therapy providing only indirect beta cell protection. We investigated whether glucagon-like peptide-1-17ß-oestradiol conjugate (GLP1-E2), a beta cell-targeted fusion compound that enhances beta cell survival and function, could potentiate a short low-dose aCD3 course in preventing autoimmune diabetes in NOD mice. We hypothesised that co-targeting immune dysregulation and beta cell fragility would provide complementary and potentially synergistic benefits, resulting in more durable protection than either monotherapy. METHODS: Female late-stage prediabetic NOD mice were randomised into four groups: untreated controls, aCD3 monotherapy, GLP1-E2 monotherapy and combination therapy. aCD3 was administered intravenously at 2.5 µg/day for 5 consecutive days, while GLP1-E2 was given subcutaneously at 100 nmol kg RESULTS: At 30 weeks of age, diabetes incidence was 77% in untreated controls, 66% in mono aCD3-treated mice and 61% in mono GLP1-E2-treated mice. Combination therapy significantly reduced diabetes incidence to 38% (p≤0.001) and delayed disease onset by 6 weeks, with sustained protection persisting for 5 weeks after treatment cessation. GLP1-E2 monotherapy reduced islet immune cell infiltration to a similar extent as aCD3 mono- and combination therapy, without affecting peripheral lymphocyte counts. Spatial transcriptomics showed increased gene responses linked to beta cell stress (Hspa5, Eif2ak3, Xbp1, Ddit3), dedifferentiation (Cd81), 'disallowed' genes (Oat, Igfbp4), antigen presentation (H2-K1, H2-Q6, H2-Ab1, H2-Eb1) and inflammation (Cxcl10, Cxcl9, Ccl5) during disease progression. These processes were attenuated by mono- and combination therapy, with aCD3 mostly restoring beta cell identity and GLP1-E2 reducing beta cell stress and immunogenicity. Staining for CD81 and TUNEL in 17-week-old treated mice revealed levels comparable to 12-week-old normoglycaemic NOD mice, while being increased in 17-week-old untreated mice. This reduced beta cell dedifferentiation and death was associated with improved beta cell protection and better preservation of beta cell mass at 26.5 weeks compared with new-onset (diabetic) mice. CONCLUSIONS/INTERPRETATION: Low-dose aCD3 or GLP1-E2 monotherapy delayed diabetes onset and preserved beta cell mass in female NOD mice, while the combination provided substantially superior protection. Simultaneously targeting immune dysregulation and beta cell vulnerability highlights the potential of combination therapy to enhance and prolong immunotherapeutic efficacy in type 1 diabetes.
2. Activation of Intestinal Type 3 Innate Lymphoid Cells and Regulatory T Cells Through Free Fatty Acid Receptor 2 Ameliorates Type 1 Diabetes in Mice.
Oral activation of FFAR2 by a synthetic agonist expanded IL-22+ and IL-2+ ILC3 and Treg cells, reinforced gut barrier function, reduced pancreatic inflammation, and ameliorated hyperglycemia in streptozotocin-induced T1D mice. Neutralization of IL-22 blunted efficacy, and in NOD mice disease onset was delayed though overall incidence was unchanged.
Impact: The study unveils an immunometabolic lever—FFAR2-driven ILC3/Treg activation—linking microbiota, barrier integrity, and islet inflammation, with clear mechanistic dependence on IL-22.
Clinical Implications: FFAR2 agonists could emerge as adjunctive therapies to delay onset or attenuate inflammation in T1D, particularly in preclinical stages; biomarker strategies may include IL-22/ILC3 readouts and gut barrier metrics.
Key Findings
- FFAR2 agonist (Cpd1) improved hyperglycemia in streptozotocin-induced T1D when given prophylactically, early therapeutically, or during established disease.
- Cpd1 increased intestinal and pancreatic ILC3 and Treg populations, enhanced gut barrier integrity, and diversified microbiota.
- IL-22 neutralization attenuated therapeutic benefit, demonstrating mechanistic dependence.
- In NOD mice, Cpd1 delayed disease initiation but did not change overall incidence.
- Cpd1 reduced α4β7-expressing inflammatory cells in pancreas while promoting gut-imprinted ILC3 accumulation.
Methodological Strengths
- Multiple treatment windows (prophylactic, early, established disease) establish robustness of effect.
- Mechanistic validation via IL-22 neutralization, barrier integrity assays, and microbiome analyses.
Limitations
- Primary efficacy shown in chemically induced T1D; in NOD mice incidence was not reduced.
- Translational relevance of Cpd1 dosing/safety in humans remains unknown.
Future Directions: Translate FFAR2 agonism to human studies with pharmacodynamic biomarkers (IL-22, ILC3/Treg signatures, gut permeability) and explore combinations with immune-modulating agents.
UNLABELLED: Reduction in intestinal type 3 innate lymphoid cells (ILC3) frequency is associated with type 1 diabetes (T1D) pathogenesis in humans and in animal models. The current study showed that, after T1D induction by multiple-low-dose streptozotocin in male C57BL/6 mice, ILC3 were reduced in both blood and pancreas and produced less IL-22 and IL-2, and a decreased proportion expressed the gut-homing α4β7 integrin in the pancreas. Additionally, T1D induction in ILC3-impaired mice produced exacerbated hyperglycemia. To activate ILC3, Compound 1 (Cpd1), a synthetic selective free fatty acid receptor 2 (FFAR2) agonist, was administered orally in a prophylactic regimen, at early therapeutic stages, or during established disease, resulting in significant amelioration of T1D symptoms. Cpd1 upregulated ILC3 and activated regulatory T cells (Treg) within the small intestine lamina propria and the pancreas, enhanced intestinal barrier integrity, and increased microbial diversity. Cpd1 also reduced α4β7-expressing inflammatory cells in the pancreas while promoting the accumulation of gut-imprinted ILC3. IL-22 was important for this anti-inflammatory response, as treatment efficacy was inhibited when mice were additionally given neutralizing anti-IL-22 antibodies. Of note, NOD mice receiving Cpd1 exhibited postponed disease initiation, but the incidence of disease was similar to that of the control group. Overall, activation of intestinal ILC3 and Treg via FFAR2 engagement, and translation of these anti-inflammatory effects to the pancreas, provided significant benefit in a mouse T1D model. ARTICLE HIGHLIGHTS: Modulating the adaptive immune response alone is insufficient for effective type 1 diabetes treatment. This study investigates targeting intestinal type 3 innate lymphoid cells as a novel therapeutic approach for type 1 diabetes. A synthetic free fatty acid receptor 2 agonist, Compound 1, activates intestinal IL-2+ and IL-22+ type 3 innate lymphoid cells and thereby reduces pancreatic inflammation, stabilizes intestinal barrier, and improves clinical outcomes in a type 1 diabetes mouse model. Compound 1 demonstrates therapeutic potential and may serve as a candidate for future clinical trials in type 1 diabetes.
3. Accumulated Safety Data of Recombinant Human Growth Hormone Therapy in Korean Children over a 10-Year Period: Interim Results from the LG Growth Study.
In a nationwide, prospective registry of 5,040 Korean children (19,878 patient-years), rhGH therapy showed low ADR (7.0%) and SADR (0.3%) rates, with malignancy incidence comparable to national expectations (SIR 1.1). Craniopharyngioma recurrence (14.3%) aligned with international experience, supporting long-term safety across multiple growth disorder etiologies.
Impact: One of the largest single-nation pediatric rhGH safety datasets to date, providing real-world evidence that aligns with international registries and informs clinicians and families.
Clinical Implications: Supports continued use of rhGH in pediatric growth disorders with routine pharmacovigilance; malignancy risk appears comparable to background rates, informing counseling and monitoring frameworks.
Key Findings
- Across 5,040 patients and 19,878 patient-years, ADRs occurred in 7.0% and SADRs in 0.3%.
- Malignancy incidence (3 cases) yielded SIR 1.1 (95% CI 0.21–2.69), comparable to national expectations.
- Craniopharyngioma recurrence occurred in 14.3% of affected patients, consistent with international registries.
- Most frequent AEs were scoliosis (1.6%), headache (0.8%), and injection site pain (0.5%).
Methodological Strengths
- Large, prospective, multicenter registry with nearly 20,000 patient-years of exposure.
- Contextualized safety signals using standardized incidence ratios and international comparisons.
Limitations
- Follow-up restricted to active treatment periods; heterogeneity in exposure duration.
- Observational design with potential reporting/selection biases and no untreated comparator.
Future Directions: Extend post-treatment surveillance to assess late events, stratify risks by etiology and dosing schedules (daily vs weekly), and harmonize safety endpoints across registries.
OBJECTIVE: To evaluate the long-term safety outcomes of recombinant human growth hormone (rhGH) administered to Korean pediatric patients with growth disorders, including growth hormone deficiency, Turner syndrome, idiopathic short stature, small for gestational age, chronic kidney disease, and Prader-Willi syndrome, using 10-year interim data from the nationwide LG Growth Study registry in the Republic of Korea. DESIGN: Prospective, multicenter, observational registry. METHODS: This interim analysis included 5,040 patients from 96 centers, representing 19,878 patient-years of treatment between November 2011 and December 2022. Although the registry spans 10 years, follow-up was limited to periods of active GH treatment and therefore varied across patients. Patients received daily or weekly rhGH. Adverse events (AEs), adverse drug reactions (ADRs), serious AEs (SAEs), and serious ADRs (SADRs) were recorded and compared with international registry data. RESULTS: Overall, AEs occurred in 34.2% of patients, ADRs in 7.0%, SAEs in 3.2%, and SADRs in 0.3%. The most frequent AE was scoliosis (1.6%), followed by headache (0.8%) and injection site pain (0.5%). Three malignant neoplasms were reported, yielding a standardized incidence ratio of 1.1 (95% confidence interval, 0.21-2.69), comparable to expected national rates. Craniopharyngioma recurrence occurred in 14.3% of affected patients, consistent with international data. CONCLUSIONS: Over 10 years, rhGH therapy in Korean pediatric patients demonstrated a low incidence of ADRs and SADRs, with malignancy and tumor recurrence rates similar to those in global registries. These findings support the long-term safety of rhGH for pediatric growth disorders, with continued surveillance warranted. SIGNIFICANCE: Using 10 years of real-world data from a pediatric registry, conducted in the Republic of Korea, this study provides one of the largest single-nation safety evaluations of rhGH therapy across multiple etiologies of short stature. The low incidence rates of ADRs and SADRs, in alignment with rates reported for other large-scale international registries, provide reassuring evidence of the safety of rhGH for clinicians and caregivers.